Sylvest Advisors LLC Invests $1.11 Million in Cencora, Inc. (NYSE:COR)

Sylvest Advisors LLC acquired a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,919 shares of the company’s stock, valued at approximately $1,105,000. Cencora makes up 0.7% of Sylvest Advisors LLC’s investment portfolio, making the stock its 22nd largest holding.

Other large investors have also recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Cencora in the 2nd quarter valued at about $1,539,000. Sanctuary Advisors LLC acquired a new position in Cencora during the 2nd quarter worth approximately $3,092,000. Centaurus Financial Inc. increased its position in shares of Cencora by 55.3% in the 2nd quarter. Centaurus Financial Inc. now owns 1,781 shares of the company’s stock valued at $401,000 after purchasing an additional 634 shares during the last quarter. Czech National Bank raised its holdings in shares of Cencora by 12.6% in the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock valued at $7,998,000 after purchasing an additional 3,990 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Cencora by 21.1% during the 3rd quarter. SG Americas Securities LLC now owns 41,762 shares of the company’s stock worth $9,400,000 after purchasing an additional 7,284 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

COR has been the topic of a number of analyst reports. Evercore ISI raised their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday. UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.40.

Cencora Stock Down 1.7 %

Shares of NYSE:COR opened at $254.11 on Friday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $261.25. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market cap of $49.11 billion, a P/E ratio of 33.84, a P/E/G ratio of 1.61 and a beta of 0.49. The firm has a fifty day moving average price of $238.74 and a 200 day moving average price of $235.90.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.87%. Cencora’s dividend payout ratio is 29.29%.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 over the last quarter. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.